Drugs / JCXH-105
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05871541 | May 2023 → Mar 2024 | herpes zoster | Immorna Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06581575 | Oct 2024 → Aug 2026 overdue | herpes zoster | Immorna Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JCXH-105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06581575 ↗ |
| Modality | Other / unclassified | “self-replicating (sr) RNA-based vaccine” NCT05871541 ↗ |
| Route | Intramuscular | “As IM injection” NCT05871541 ↗ |